Clinical Trial Update: A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) [Phase 3]

View source ↗

Summary

Phase 3 randomized trial evaluating gemcitabine + nab-paclitaxel (GnP) with SBRT and serplulimab versus GnP alone as first-line therapy for recurrent or metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Serplulimab (serplulimab)

Snippet

Sponsor: West China Hospital | Conditions: PDAC - Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING